


N-deacetylated BMS-202

Cat. No.:	HY-19745A		
CAS No.:	2310135-18-1		
Molecular Formula:	C ₂₃ H ₂₇ N ₃ O ₂		
Molecular Weight:	377.48		
Target:	PD-1/PD-L1		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 36 mg/mL (95.37 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.6491 mL	13.2457 mL	26.4915 mL
	5 mM	0.5298 mL	2.6491 mL	5.2983 mL
	10 mM	0.2649 mL	1.3246 mL	2.6491 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.

In Vitro

BMS-202 inhibits PD-1/PD-L1 interaction, and may augment therapeutic immune response to a number of histologically distinct tumors. Blockade of the PD-1/PD-L1 ligation using antibodies to PD-L1 has been shown to restore and augment T cell activation in many systems^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WO2015034820 A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA